newsfilter
← Earnings
Earnings Releases·

Erasca — Third Quarter 2026 Earnings Summary

  • Cash, cash equivalents, and marketable securities increased to $947.8 million as of September 30, 2026, from $341.8 million at year-end 2025, following a $632.5 million gross proceeds public offering completed in July 2026.
  • Net loss widened to $51.3 million ($0.15 per share) for the quarter ended September 30, 2026, compared to $30.6 million ($0.11 per share) in the prior year period, driven by a 110% increase in R&D expenses to $47.2 million.
  • ERAS-0015 received FDA Fast Track Designation in August 2026 for metastatic pancreatic adenocarcinoma, while preliminary data for ERAS-4001 and ERAS-4015 are expected in the second half of 2026 and first half of 2027, respectively.
  • Management appointed Charles Fuchs as president of R&D and David Chonzi as senior vice president of global pharmacovigilance in August 2026, citing confidence in executing upcoming Phase 3 trials in PDAC and RASm NSCLC with current cash reserves.
Company
ERASCA INC
Sector
Healthcare
Industry
Biotechnology